Pearson


03/05/21 -"We have slightly raised our target price following what we judge as an encouraging Q1 21 trading update (please refer to our 26/04/2021 Latest). Going forward, vaccination, which has been strong in ..."

Pages
52
Language
English
Published on
03/05/21
You may also be interested by these reports :
07/05/21
As our target price has been cut, our recommendation moves from Add to Reduce. We reiterate our cautious view on the stock, recently mostly driven by ...

07/05/21
Our EPS21e is cut as we reduced our sales and adjusted our OP forecasts for FY21e, after management provided a rather conservative outlook, with only ...

05/05/21
Q1 21 was characterised by opposing trends at ITV Studios and advertising. Revenue recovered at ITV Studios (+9%), while advertising decreased (-6%) ...

05/05/21
Wolters Kluwer published a very solid Q1 trading update with reassuring operating trends despite the tough pandemic context. The FY21e guidance is ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO